Alx Oncology Holdings (ALXO) FCF Margin (2019 - 2020)

Alx Oncology Holdings (ALXO) reported FCF Margin of 1169.45% for Q2 2020, up 14.63% sequentially from 1369.92% in Q1 2020.

Alx Oncology Holdings (ALXO) FCF Margin (2019 - 2020) Analysis & Trends

Alx Oncology Holdings (ALXO) has 2 years of FCF Margin data on file, last reported at 1169.45% in Q2 2020.

For the quarter ending Q2 2020, FCF Margin changed N/A year-over-year to 1169.45%; the trailing twelve-month figure through Mar 2021 stood at 6544.4% (down 620562.0% YoY), and the FY2020 full-year result was 3241.96%, down 293750.0% from the prior year.
FCF Margin grew to 1169.45% in Q2 2020, from 1369.92% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 231.82% in Q4 2019 to a low of 1369.92% in Q1 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alx Oncology Holdings	211.24 Mn	211.24 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2020	-1,169.45%
Mar 31, 2020	-1,369.92%
Dec 31, 2019	-231.82%
Sep 30, 2019	-253.66%